Treating patients with aspirin after completion of standard adjuvant therapy for colorectal cancer failed to significantly ...

Bayer is pressing ... given alongside aspirin plus a P2Y12 inhibitor – at one year. Once again, there was no significant observed increase in bleeding with asundexian at any dose or compared ...

For decades, taking low-dose aspirin every day was widely recommended as an easy way to prevent heart attacks and strokes. But that advice has changed.

People without the risk of heart problems who consumed daily low-dose aspirin, it increased the chance of bleeding in the ...

As low-dose prophylactic aspirin therapy becomes common among older people, potential risks that are associated with such treatment assume increasing importance. In particular, some clinicians are ...

The ARIES-HM3 substudy may help persuade implanters who are less well-versed in the circulatory changes an LVAD affords.

A Washington jury on Tuesday ordered Bayer to pay $100 million to four people who say they were sickened by toxic chemicals ...

Description The goal of the trial was to evaluate treatment with famotidine compared with placebo among patients taking low-dose aspirin. Hypothesis Famotidine would be more effective in ...

Although Bayer’s top-selling drug Xarelto lost market exclusivity in most geographies in 2024, the company still predicts it will see strong growth from the pharma business unit beginning in 2027.